Athersys, Inc. (NASDAQ: ATHX) is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. The company’s focus is on the treatment of medical conditions where there is significant unmet clinical need. It is particularly focused on developing therapies in the regenerative medicine area, and is developing MultiStem, a patented, adult-derived “off-the-shelf” stem cell product platform for multiple disease indications in the areas of neurological, cardiovascular disease, inflammatory and immune disease, as well as other areas. For more information, visit the company’s website at www.athersys.com.